Measurement of Retinal Nerves and Blood Vessels as Markers for Type 1 Diabetes
测量视网膜神经和血管作为 1 型糖尿病的标志物
基本信息
- 批准号:9754819
- 负责人:
- 金额:$ 50.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAxonBiological MarkersBlood VesselsBlood capillariesBostonCharacteristicsClinicClinicalClinical EngineeringClinical ManagementCollaborationsComplexComplications of Diabetes MellitusDataDetectionDiabetes MellitusDiabetic RetinopathyDiagnosisDiagnosticDiseaseDisease MarkerDisease ProgressionEarly DiagnosisEvolutionFiber OpticsFundingHistopathologyHuman VolunteersImageImageryImaging TechniquesImaging technologyIncidenceInsulin-Dependent Diabetes MellitusKnowledgeLaboratory ResearchLasersLightMarket ResearchMeasurementMedicalMetabolicModalityMonitorMorphologic artifactsMorphologyNerveNerve FibersNeuronsOphthalmologistOphthalmoscopyOptical Coherence TomographyPatientsPediatric HospitalsPericytesPhasePhotoreceptorsPopulationPositioning AttributePublicationsRecording of previous eventsReperfusion TherapyResearchResearch PersonnelResolutionRetinaRetinalScanningSchemeStructureSystemTechniquesTechnologyTestingTissuesTractionTreatment EfficacyUnited States National Institutes of HealthVisionVision researchadaptive opticsadaptive optics scanning laser ophthalmoscopybaseclinical Diagnosisclinical investigationcommercializationdesigndisease diagnosisearly detection biomarkersfundamental researchhealthy volunteerhigh resolution imagingimagerimaging approachimaging capabilitiesimaging modalityimaging platformimprovedin vivoinstrumentmultimodalityneurovascularnew technologynext generationnon-invasive imagingnoveloptical imagingphysical scienceprogramsprototyperetina blood vessel structureretinal imagingspecific biomarkerstooltreatment responsevolunteer
项目摘要
Project Summary/Abstract
There is currently a significant need for new non-invasive imaging techniques able to accurately
quantify biomarkers for early detection, diagnosis, and quantification of complications in type 1 diabetes
(T1D) such as diabetic retinopathy (DR). Physical Sciences Inc. (PSI) proposes to develop an imaging
platform based on a new detection arrangement retrofitted to an existing high-resolution retinal imaging
platform that includes adaptive optics-assisted scanning laser ophthalmoscopy (AO-SLO) and Optical
Coherence Tomography (OCT). The new technique will allow for visualization and quantification of blood
vessels structure and nerve bundle arrangement with exquisite details afforded by AO. The proposed
detection scheme will be first tested and demonstrated using an existing multimodal AO retinal imager
(MAORI) in Phase I and then in Phase II a new MAORI prototype will be developed specifically for imaging
particular characteristics of retinal alterations induces by diabetes. Specific biomarkers for T1D
complications will be defined based on patient data acquired by our collaborators from Boston Children's
Hospital. About 40 patients with different stages of DR will be imaged during the Phase II Program.
PSI has a long, successful history of developing and commercializing high-resolution retinal imagers for
the ophthalmic research market. PSI and our collaborators have recognized that one of the main
impediments in developing a clinical market for AO-SLO's is that there have been few in-depth studies on
the medical application of AO imagers for disease diagnosis and tracking the efficacy of treatments.
Despite a relatively large number of research publications on the benefits of AO on understanding
fundamental aspects of vision, so far AO has not gained traction in the clinical market. However, given the
large incidence of neurovascular diseases, it is possible that the proposed application to use high-
resolution retinal imaging to investigate the retinal changes due to diabetes will generate significant drive to
bring AO closer to the clinical market. Therefore, PSI is requesting funding for developing this technology
with a potentially significant impact on vision research and subsequently on the clinical diagnosis and
management of DR.
项目摘要/摘要
目前非常需要新的非侵入式成像技术
用于1型糖尿病并发症早期检测、诊断和量化的生物标志物
(T1D)如糖尿病视网膜病变(DR)。物理科学公司(PSI)建议开发一种成像
基于改装成现有高分辨率视网膜成像的新检测装置的平台
包括自适应光学辅助扫描激光眼底镜(AO-SLO)和光学的平台
相干断层扫描(OCT)。这项新技术将允许血液的可视化和量化
血管结构和神经束排列,由AO提供精致的细节。建议数
检测方案将首先使用现有的多模式光学视网膜成像仪进行测试和演示
(毛利语)在第一阶段,然后在第二阶段,将专门为成像开发新的毛利人原型
糖尿病引起的视网膜改变的特殊特征。T1D的特异性生物标志物
并发症的定义将基于我们的合作者从波士顿儿童医院获得的患者数据
医院。在第二阶段计划期间,将对大约40名不同阶段的DR患者进行成像。
PSI在开发和商业化高分辨率视网膜成像仪方面有着悠久而成功的历史
眼科研究市场。PSI和我们的合作者已经认识到,主要的
发展AO-SLO临床市场的障碍是,很少有深入的研究
声学造影仪在疾病诊断和治疗效果跟踪中的医学应用。
尽管有相对较多的关于AO的好处的研究出版物
视力的基本方面,到目前为止,AO还没有在临床市场上获得吸引力。然而,鉴于
神经血管疾病发病率大,有可能建议应用高-
分辨率视网膜成像研究糖尿病引起的视网膜变化将产生巨大的驱动力
使AO更接近临床市场。因此,PSI正在申请资金来开发这项技术
可能会对视觉研究以及随后的临床诊断和
对DR的管理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mircea Mujat其他文献
Mircea Mujat的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mircea Mujat', 18)}}的其他基金
Evaluation of photoreceptors health and function in diabetic retinopathy patients using a high-resolution retinal imaging device with controlled light stimulus
使用受控光刺激的高分辨率视网膜成像设备评估糖尿病视网膜病变患者的光感受器健康和功能
- 批准号:
10696696 - 财政年份:2023
- 资助金额:
$ 50.47万 - 项目类别:
Ultra-high speed AO-OCT clinical system to image ganglion cells and microglia
超高速 AO-OCT 临床系统对神经节细胞和小胶质细胞进行成像
- 批准号:
10547181 - 财政年份:2022
- 资助金额:
$ 50.47万 - 项目类别:
Ultra-high speed AO-OCT clinical system to image ganglion cells and microglia
超高速 AO-OCT 临床系统对神经节细胞和小胶质细胞进行成像
- 批准号:
10705315 - 财政年份:2022
- 资助金额:
$ 50.47万 - 项目类别:
Versatile Eye Tracking for Improved High-resolution Retinal Imaging
多功能眼动追踪可改善高分辨率视网膜成像
- 批准号:
10154113 - 财政年份:2021
- 资助金额:
$ 50.47万 - 项目类别:
Multispectral cellular-level retinal imaging for early detection of Alzheimer’s disease
用于早期检测阿尔茨海默病的多光谱细胞水平视网膜成像
- 批准号:
10323717 - 财政年份:2021
- 资助金额:
$ 50.47万 - 项目类别:
Comprehensive imaging and quantification of blood flow for investigating ocular diseases without additional contrast agent
无需额外造影剂即可对血流进行全面成像和量化以研究眼部疾病
- 批准号:
10295545 - 财政年份:2019
- 资助金额:
$ 50.47万 - 项目类别:
Comprehensive imaging and quantification of blood flow for investigating ocular diseases without additional contrast agent
无需额外造影剂即可对血流进行全面成像和量化以研究眼部疾病
- 批准号:
10349594 - 财政年份:2019
- 资助金额:
$ 50.47万 - 项目类别:
Multi-modal AO-LSO Phase Gradient Imaging of the Inner Retina
内视网膜多模态 AO-LSO 相位梯度成像
- 批准号:
9788095 - 财政年份:2014
- 资助金额:
$ 50.47万 - 项目类别:
Combined RCM and PSOCT for skin cancer imaging
结合 RCM 和 PSOCT 进行皮肤癌成像
- 批准号:
8534059 - 财政年份:2012
- 资助金额:
$ 50.47万 - 项目类别:
Combined RCM and PSOCT for skin cancer imaging
结合 RCM 和 PSOCT 进行皮肤癌成像
- 批准号:
8251261 - 财政年份:2012
- 资助金额:
$ 50.47万 - 项目类别:
相似海外基金
An atypical microtubule generation mechanism for neurons drives dendrite and axon development and regeneration
神经元的非典型微管生成机制驱动树突和轴突的发育和再生
- 批准号:
23K21316 - 财政年份:2024
- 资助金额:
$ 50.47万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Characterizing Wnt Signaling Pathways in Axon Guidance
轴突引导中 Wnt 信号通路的特征
- 批准号:
10815443 - 财政年份:2023
- 资助金额:
$ 50.47万 - 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
- 批准号:
10896844 - 财政年份:2023
- 资助金额:
$ 50.47万 - 项目类别:
Does phosphorylation regulation of the axon initial segment cytoskeleton improve behavioral abnormalities in ADHD-like animal models?
轴突起始段细胞骨架的磷酸化调节是否可以改善 ADHD 样动物模型的行为异常?
- 批准号:
23KJ1485 - 财政年份:2023
- 资助金额:
$ 50.47万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Loss-of-function variants of the axon death protein SARM1 and protection from human neurodegenerative disease
轴突死亡蛋白 SARM1 的功能丧失变体和对人类神经退行性疾病的保护
- 批准号:
2891744 - 财政年份:2023
- 资助金额:
$ 50.47万 - 项目类别:
Studentship
Collaborative Research: Evolution of ligand-dependent Robo receptor activation mechanisms for axon guidance
合作研究:用于轴突引导的配体依赖性 Robo 受体激活机制的进化
- 批准号:
2247939 - 财政年份:2023
- 资助金额:
$ 50.47万 - 项目类别:
Standard Grant
Understanding the degeneration of axon and nerve terminals in Alzheimer's disease and related dementia brain
了解阿尔茨海默病和相关痴呆大脑中轴突和神经末梢的变性
- 批准号:
10661457 - 财政年份:2023
- 资助金额:
$ 50.47万 - 项目类别:
Unlocking BIN1 function in oligodendrocytes and support of axon integrity
解锁少突胶质细胞中的 BIN1 功能并支持轴突完整性
- 批准号:
10901005 - 财政年份:2023
- 资助金额:
$ 50.47万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 50.47万 - 项目类别:
The role of RNA methylation in cytoskeleton regulation during axon development
RNA甲基化在轴突发育过程中细胞骨架调节中的作用
- 批准号:
22KF0399 - 财政年份:2023
- 资助金额:
$ 50.47万 - 项目类别:
Grant-in-Aid for JSPS Fellows